Dual Modulators Of 5HT2A and D3 Receptors

A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I):

• wherein:
• each X is independently halogen, cyano;
• C1-6-alkyl, C1-6-alkoxy or C1-6-haloalkyl;
• n is 0, 1, 2 or 3;
• R1 is H or C1-6-alkyl;
• R2 is
• R3 is hydrogen, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C1-6-alkoxy, C3-10-cycloalkyl, aryl, 4 to 10 membered heterocycloalkyl, or 5 to 10 membered heteroaryl, each of which is optionally substituted by one to five substituents selected from the group consisting of:
• halo,
• cyano,
• —SO2—C1-6-alkyl,
• hydroxyl,
• C1-6-alkyl,
• C1-6-haloalkyl,
• —CO(O)—C1-6-alkyl,
• C1-6-alkoxy optionally substituted by one or more Ra,
• C3-10-cycloalkyl optionally substituted by one or more Ra,
• 4 to 10 membered heterocycloalkyl optionally substituted by one or more Ra,
• aryl optionally substituted by one or more Ra,
• 5 to 10 membered heteroaryl optionally substituted by one or more Ra, and
• —NRbRc,
• wherein Rb is H or C1-6-alkyl and wherein Rc is H, C1-6-alkyl or aryl optionally substituted by one or more Ra;
• wherein Ra is selected from:
• halo,
• cyano,
• oxo,
• hydroxyl,
• halobenzenesulfonyl,
• C1-6-alkyl
• C1-6-haloalkyl,
• —NH(CO)—C1-6-alkyl,
• di(C1-6)alkylamino,
• —O(CO)—C1-6-alkyl,
• C1-6-alkylsulfonyl,
• C1-6-alkoxy
• C1-6-haloalkoxy,
• 4 to 10 membered heterocycloalkyl
• aryl,
• aryloxy, and
• 5 to 10 membered heteroaryl;
• or a pharmaceutically acceptable salt thereof
• and a pharmaceutically acceptable carrier.